All Stories

AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe

As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China, the company's China business logged a sales decline in the fourth quarter of 2024.

Feb 9, 2025 - 21:43
 0
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China, the company's China business logged a sales decline in the fourth quarter of 2024.
Read More

Tags:

Previous Article

Nephrologists already aboard GLP-1 bandwagon, providing launchpad for Ozempic in...

Next Article

Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs

Related Posts

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid HHS handover: report

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid ...

Feb 20, 2025  0

A heartwarming roundup of cardiovascular news and most-loved stories

A heartwarming roundup of cardiovascular news and most-...

Feb 14, 2025  0

FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more

FDA dings Piramal API plant with Form 483 detailing pro...

Feb 26, 2025  0